Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval ...
Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danzitenâ„¢, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback